

青少年强直性脊柱炎早期年龄、身高、体重、体重指数与腰椎骨量、骨密度的相关性初步分析

马兴 胡蕴玉 吴小明 王全平 李晓娟 吕荣 王军 徐新智

【摘要】 目的 研究青少年强直性脊柱炎(Ankylosing spondylitis, AS)早期年龄、身高、体重、体重指数(BMI)与腰椎骨矿含量(L₁₋₄ BMC、L₂₋₄ BMC)、腰椎面积骨密度(L₁₋₄ BMD、L₂₋₄ BMD)、腰椎体积表观骨密度(L₁₋₄ BMAD、L₂₋₄ BMAD)之间的相关性,旨在初步探讨我国青少年 AS 早期骨量、骨密度的重要相关因素及评价指标。方法 选择男性青少年 AS 早期患者 31 例,统计 AS 患者年龄(y)、身高(cm)、体重(kg)、BMI(kg/m²)、病程(mon)及 ESR (mm/h)等变量,应用 DPX - IQ 双能 X 线骨密度仪(DEXA)检测 L₁₋₄ BMC、L₂₋₄ BMC、L₁₋₄ BMD 和 L₂₋₄ BMD,计算 L₁₋₄ BMAD 和 L₂₋₄ BMAD(BMAD = BMC/面积^{3/2}, g/cm³);采用相关和回归分析研究多因素相关性。结果 年龄、身高、体重、BMI、病程、ESR、L₁₋₄ BMC、L₂₋₄ BMC、L₁₋₄ BMD、L₂₋₄ BMD、L₁₋₄ BMAD 和 L₂₋₄ BMAD 的变量值分别为(17.56 ± 2.01)y、(168.52 ± 8.59) cm、(56.13 ± 12.72) kg、(19.65 ± 3.42) kg/m²、(19.61 ± 12.39) mon、(21.71 ± 10.04) mm/h、(52.16 ± 12.17) g、(41.29 ± 9.59) g、(0.971 ± 0.139) g/cm²、(0.984 ± 0.142) g/cm²、(0.1332 ± 0.0146) g/m³ 和(0.1527 ± 0.0173) g/m³。双因素相关分析初步证实 AS 早期 ESR 增高(51.61% AS 患者 ESR ≥ 20 mm/h)且与腰椎骨量、骨密度呈负相关($r = -0.509 \sim -0.424, P = 0.003 \sim 0.018$)。多因素回归分析表明仅体重因素进入 L₁₋₄ BMD($R = -0.657, P = 0.000$)、L₂₋₄ BMD($R = 0.620, P = 0.000$)、L₁₋₄ BMAD($R = 0.551, P = 0.001$)和 L₂₋₄ BMAD($R = 0.510, P = 0.003$)回归方程;另一方面,身高因素成为 L₁₋₄ BMC($R = 0.676, P = 0.000$)和 L₂₋₄ BMC($R = 0.673, P = 0.000$)主要相关因素而被纳入其回归方程。结论 身高和体重即成为青少年 AS 早期骨量及骨密度的重要相关因素。此时期重视发挥二因素对腰椎骨矿含量和骨密度的正相关作用,将对于减缓青少年 AS 早期骨量丢失及 AS 相关性骨质疏松症有积极意义。

【关键词】 青少年;强直性脊柱炎;骨密度;身高;骨质疏松症;体重

Effects of age, height, weight and BMI on lumbar spinal bone mineral contents and densities in Chinese adolescents with early ankylosing spondylitis MA Xing, HU Yunyu, WU Xiaoming, et al. Institute of Orthopaedic Surgery of PLA & Department of Orthopaedics, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China

【Abstract】 **Objective** To study the possible effects of age, height, weight and body mass index (BMI) on lumbar spinal bone mineral contents (L₁₋₄ BMC, L₂₋₄ BMC), areal bone mineral densities (L₁₋₄ BMD, L₂₋₄ BMD), and volumetric bone mineral apparent densities (L₁₋₄ BMAD, L₂₋₄ BMAD) of Chinese adolescents with early ankylosing spondylitis (AS). **Methods** Thirty-one male Chinese adolescent outpatients with early AS were included. Age (y), height (cm), total body weight (kg), body mass index (BMI, kg/m²), disease duration (mon), and erythrocyte sedimentation rate (ESR, mm/h) of AS patients were recorded. L₁₋₄ BMD, L₂₋₄ BMC, L₁₋₄ BMD, and L₂₋₄ BMD were evaluated by dual-energy X-ray absorptiometry (DEXA) using Lunar DPX-IQ device. L₁₋₄ BMAD and L₂₋₄ BMAD (BMAD = BMC/Area^{3/2}, g/cm³) were subsequently calculated. Correlation and multiple regression analyses were performed. **Results** The values of age, height, weight, BMI, disease duration, ESR, L₁₋₄ BMC, L₂₋₄ BMC, L₁₋₄ BMD, L₂₋₄ BMD, L₁₋₄ BMAD, and BMAD were 17.56 ± 2.01y, 168.52 ± 8.59 cm, 56.13 ± 12.72 kg,

作者单位:710032 西安,第四军医大学西京医院全军骨科研究所(马兴、胡蕴玉、王全平、李晓娟、吕荣、王军、徐新智);第四军医大学生物医学工程系卫生装备计量学教研室(吴小明)

19.65 ± 3.42 kg/m², 19.61 ± 12.39 mon, 21.71 ± 10.04 mm/h, 52.16 ± 12.17 g, 41.29 ± 9.59 g, 0.971 ± 0.139 g/cm², 0.984 ± 0.142g/cm², 0.1332 ± 0.0146 g/m³, and 0.1527 ± 0.0173 g/m³ respectively. In AS patients, raised ESR (51.61% of patients had ESR ≥ 20 mm/h) was negatively correlated with lumbar spinal bone mineral contents and densities ($r = -0.509 \sim -0.424, P = 0.003 \sim 0.018$). Multiple regression analysis further identified that only the factor of weight had predominant influences on L₁₋₄BMD ($R = 0.657, P = 0.000$), L₂₋₄BMD ($R = 0.620, P = 0.000$), L₁₋₄BMAD ($R = 0.551, P = 0.001$) and L₂₋₄BMAD ($R = 0.510, P = 0.003$), and the factor of height had positively determinant effects on both L₁₋₄BMC ($R = 0.676, P = 0.000$) and L₂₋₄BMC ($R = 0.673, P = 0.000$). **Conclusion** Positive and protective effects of height and weight on lumbar spinal bone mass and densities contribute favorably to early prevention of AS-associated spinal bone loss and osteoporosis.

[Key words] Adolescence; Ankylosing spondylitis; Bone mineral density; Height; Osteoporosis; Weight

青少年时期是人体生长发育的第二个高峰期,对骨骼成长及峰值骨量获取具有极其的重要意义^[1,2]。然而,此时期好发的强直性脊柱炎(Ankylosing spondylitis, AS)将对青少年骨关节造成严重损害。其中 AS 相关性骨质疏松症(Osteoporosis, OP)是一种威胁青少年生长发育及健康成长的严重炎症性、免疫性的脊柱及关节疾患,病程进展将导致和遗留严重骨骼畸形及多器官损害。AS 相关性骨质疏松症作为 AS 严重并发症之一,已日益受到关注^[3-5]。但是,青少年尤其是我国青少年 AS 早期骨量变化特点尚无确切研究。本研究通过分析 31 例青少年 AS 早期患者的年龄、身高、体重、体重指数(BMI)与腰椎骨矿含量(L₁₋₄ BMC、L₂₋₄ BMC)、腰椎面积骨密度(L₁₋₄ BMD、L₂₋₄ BMD)、腰椎体积表观骨密度(L₁₋₄ BMAD、L₂₋₄ BMAD)的相关性,旨在初步探讨适合我国青少年 AS 早期骨量、骨密度研究的相关因素和评价指标。

材料和方法

1. 研究对象:自 2000 年 1 月至 2003 年 10 月,择取男性青少年 AS 早期患者 31 例。AS 患者均符合下列入选标准:(1) AS 纽约诊断标准^[6];(2)血清 HLA-B27(+)^[7,8];(3)无明显脊柱侧弯、增生、韧带骨化或竹节样改变,无烟酒嗜好,否认其它血清阴性关节炎,否认服用激素、巴比妥类和其他影响骨代谢等药物,除外特殊补钙治疗、超常体力活动、先天性骨骼畸形、严重肝、肾疾病、糖尿病、骨肿瘤、佝偻病、骨软化症等。

2. 临床和影像分析指标:基本临床资料包括:年龄(y)、身高(cm)、体重(kg)、BMI(kg/m²)和病程(月)。采用近期(≤2 月内)影像学资料,按照纽约标准评估髋髂关节炎,早期髋髂关节炎诊断采用 CT 扫描。

3. 实验室检查:检测 AS 患者血清 HLA-B27 及红细胞沉降率(ESR, mm/h)。

4. DEXA:受检者取仰卧屈髋屈膝位,采用 Lunar DPX-IQ 双能 X 线骨密度测量仪(DEXA)测定 L₁₋₄ BMC、L₂₋₄ BMC、L₁₋₄ BMD 和 L₂₋₄ BMD,计算 L₁₋₄ BMAD 和 L₂₋₄ BMAD(BMAD = BMC/面积^{3/2}, g/cm³)。变异系数(CV) 1%,每日开机后用厂家提供的体模进行仪器检测质量校验。

5. 统计学处理:

(1)年龄、身高、体重、BMI、病程、ESR、L₁₋₄ BMC、L₂₋₄ BMC、L₁₋₄ BMD、L₂₋₄ BMD、L₁₋₄ BMAD 及 L₂₋₄ BMAD 正态性检验。变量值用均数 ± 标准差表示。

(2)AS 组内简单双因素以及多因素相关分析, $P < 0.01$ 差异有显著性。

应用 SPSS10.0 统计软件建立数据库并进行相关和回归分析。

结 果

1. 变量值及结果经正态性检验各变量均符合正态分布。青少年 AS 早期患者 ESR 增高(21.71 ± 10.04) mm/h,其中 51.61% (16/31) 患者 ESR ≥ 20 mm/h,见表 1。

表 1 AS 患者变量值统计结果

变量	n	$\bar{x} \pm s$	Z	P^{K-S}
年龄(y)	31	17.56 ± 2.01	0.701	0.709
身高(cm)	31	168.52 ± 8.59	0.854	0.459
体重(kg)	31	56.13 ± 12.72	1.076	0.198
BMI(kg/m ²)	31	19.65 ± 3.42	0.658	0.779
病程(mon)	31	19.61 ± 12.39	0.898	0.395
ESR(mm/h) ^{nt}	31	21.71 ± 10.04	0.965	0.309
L ₁₋₄ BMC(g)	31	52.16 ± 12.17	0.541	0.931
L ₂₋₄ BMC(g)	31	41.29 ± 9.59	0.557	0.916
L ₁₋₄ BMD(g/cm ²)	31	0.971 ± 0.139	0.494	0.968
L ₂₋₄ BMD(g/cm ²)	31	0.984 ± 0.142	0.531	0.941
L ₁₋₄ BMAD(g/cm ³)	31	0.1332 ± 0.0146	0.777	0.582
L ₂₋₄ BMAD(g/cm ³)	31	0.1527 ± 0.0173	0.946	0.332

注: P^{K-S} : K-S(Kolmogorov-Smirnov) 适配度检验 P 值; Z: K-SZ 值

2. 简单双因素相关分析初步证实了腰椎骨量、

骨密度之间具有良好的正相关性。其中, $L_{1-4}BMC$ 与 $L_{1-4}BMD$ ($r = 0.939, P = 0.000$)、 $L_{1-4}BMAD$ ($r = 0.740, P = 0.000$)均显著正相关; $L_{1-4}BMD$ 与 $L_{1-4}BMAD$ ($r = 0.925, P = 0.000$)显著正相关。此外, $L_{2-4}BMC$ 与 $L_{2-4}BMD$ ($R = 0.938, P = 0.000$)、 $L_{2-4}BMAD$ ($r = 0.742, P = 0.000$)均显著正相关, 且 $L_{2-4}BMD$ 与 $L_{2-4}BMAD$ ($r = 0.929, P = 0.000$)亦显著正相关。体重则与身高 ($r = 0.608, P = 0.000$)以及 BMI ($r = 0.892, P = 0.000$)显著正相关。另一方面, ESR 增高 ($21.71 \pm 10.04\text{mm/h}$, 51.61% AS 患者 $ESR \geq 20\text{mm/h}$)且与 $L_{1-4}BMC$ 、 $L_{2-4}BMC$ 、 $L_{1-4}BMD$ 、 $L_{2-4}BMD$ 、 $L_{1-4}BMAD$ 及 $L_{2-4}BMAD$ ($r = 0.497, P = 0.006$; $r = 0.484, P = 0.006, r = -0.509, P = 0.003$; $r = -0.492, P = 0.005$; $r = -0.455, P = 0.010$ 和 $r = -0.424, P = 0.018$)均呈负

相关。

3. 多因素相关回归分析进一步证实, 在众多因素中身高 ($R = 0.608, P = 0.000$)和 BMI ($R = 0.350, P = 0.009$)进入 $L_{1-4}BMC$ 回归方程 ($R = 0.759, \text{Radj}^2 = 0.545, P = 0.000$)。身高因素不仅是 $L_{1-4}BMC$ ($R = 0.676, \text{Radj}^2 = 0.439, P = 0.000$)主要相关因素而且是唯一被纳入 $L_{2-4}BMC$ ($R = 0.673, \text{Radj}^2 = 0.434, P = 0.000$)回归方程的变量因素。体重则是唯一被纳入 $L_{1-4}BMD$ ($R = 0.657, \text{Radj}^2 = 0.412, P = 0.000$)、 $L_{2-4}BMD$ ($R = 0.620, \text{Radj}^2 = 0.363, P = 0.000$)、 $L_{1-4}BMAD$ ($R = 0.551, \text{Radj}^2 = 0.280, P = 0.001$)以及 $L_{2-4}BMAD$ ($R = 0.510, \text{Radj}^2 = 0.235, P = 0.003$)回归方程的显著正相关因素, 见表 2。

表 2 多因素回归分析结果 ($n = 31$)

项目	$L_{1-4}BMC$		$L_{2-4}BMC$		$L_{1-4}BMD$		$L_{2-4}BMD$		$L_{1-4}BMAD$		$L_{2-4}BMAD$	
	β	P	β	P	β	P	β	P	β	P	β	P
年龄	-	-	-	-	-	-	-	-	-	-	-	-
身高	0.608	0.000	0.673	0.000	-	-	-	-	-	-	-	-
体重	-	-	-	-	0.657	0.000	0.620	0.000	0.551	0.001	0.510	0.003
BMI	0.350	0.009	-	-	-	-	-	-	-	-	-	-
病程	-	-	-	-	-	-	-	-	-	-	-	-
ESR	-	-	-	-	-	-	-	-	-	-	-	-
R	0.759	-	0.673	-	0.657	-	0.620	-	0.551	-	0.510	-
R^2	0.575	-	0.452	-	0.431	-	0.384	-	0.304	-	0.260	-
Radj^2	0.545	-	0.434	-	0.412	-	0.363	-	0.280	-	0.235	-
P	0.000	-	0.000	-	0.000	-	0.000	-	0.000	-	0.003	-

注: β : 变量的标准系数; R: 相关系数; R^2 : 决定系数; Radj^2 : 调整决定系数; P: 显著性 P 值; -: 无显著性, 该变量未进入回归方程

讨 论

强直性脊柱炎 (Ankylosing spondylitis, AS) 以其发病早、易导致和遗留严重骨骼畸形, 而成为威胁青少年生长发育的一种严重脊柱及关节疾患。AS 相关性骨质疏松症 (Osteoporosis, OP) 不仅是骨骼系统严重并发症之一, 还是脊柱畸形、压缩性骨折以及容易合并脊髓损伤的重要危险因素^[4,9-11]。目前有关急性期炎性反应指标如 ESR 与 AS 相关性的研究屡见不鲜。近来有研究提示急性炎性反应指标不仅与 AS 活动性有关, 而且 ESR 增高可能预示着骨吸收增强。本研究不仅发现该组青少年 AS 早期患者 ESR 显著增高, 31 例患者中有 16 例 (51.61%) $ESR \geq 20\text{mm/h}$ ^[12]、11 例 (35.48%) $ESR \geq 25\text{mm/h}$ ^[13]; 而且明确证实了增高的 ESR 与腰椎骨矿含量、骨密度显著负相关性 ($r = -0.509 \sim -0.424, P = 0.003 \sim$

0.018), 进而为上述论点提供了重要直接依据^[12,14,15]。

另一方面, 年龄、身高、体重和体重指数 (BMI) 是青少年成长发育密切相关的个体化特征基本要素, 深入研究该要素与骨量和骨密度的相关性, 将有助于早期、全面、正确评估青少年 AS 骨量、骨强度变化特点及远期骨质疏松危险性^[4]。

虽然 AS 早期骨密度下降可能是疾病本身炎症所引起的^[12,14,15], 但是本研究证实, 在众多因素中仅有体重因素被严格纳入 $L_{1-4}BMD$ ($R = 0.657, \text{Radj}^2 = 0.412, P = 0.000$)、 $L_{2-4}BMD$ ($R = 0.620, \text{Radj}^2 = 0.363, P = 0.000$)、 $L_{1-4}BMAD$ ($R = 0.551, \text{Radj}^2 = 0.280, P = 0.001$) 和 $L_{2-4}BMAD$ ($R = 0.510, \text{Radj}^2 = 0.235, P = 0.003$) 回归方程, 即体重决定 24% ~ 41% 腰椎密度的变化。另一方面, 身高作为 $L_{1-4}BMD$ (身高 $R = 0.676, \text{Radj}^2 = 0.439, P = 0.000$) 和 $L_{2-4}BMC$

($R = 0.673$, $\text{Rad}^2 = 0.434$, $P = 0.000$)的关键相关因素,决定了44%腰椎骨矿量的变化。身高和体重即对青少年AS早期骨矿含量和骨密度有着极其重要的正相关意义。进而提示,如果能在积极治疗AS的同时,正确开展康复训练及促进青少年成长发育,将有利于发挥身高和体重对骨矿含量和骨密度的正相关作用,对于维持和增加骨量和骨密度、改善骨强度、降低AS相关性骨质疏松及骨折危险性都大有裨益。

参 考 文 献

- 1 Saggese G, Baroncelli GI, Bertelloni S. Osteoporosis in children and adolescents: diagnosis, risk factors, and prevention. *J Pediatr Endocrinol Metab*. 2001, 14: 833-859.
- 2 Baroncelli GI, Federico G, Bertelloni S, et al. Bone quality assessment by quantitative ultrasound of proximal phalanges of the hand in healthy subjects aged 3-21 years. *Pediatr Res*, 2001, 49: 713-718.
- 3 Maillefert JF, Aho LS, El Maghraoui A, et al. Changes in bone density in patients with ankylosing spondylitis: a two-year follow-up study. *Osteoporos Int*, 2001, 12: 605-609.
- 4 Capaci K, Hegguler S, Argin M, et al. Bone mineral density in mild and advanced ankylosing spondylitis. *Yonsei Med J*, 2003, 44: 379-384.
- 5 Gratacos J, Collado A, Pons F, et al. Significant loss of bone mass in patients with early, active ankylosing spondylitis: a followup study. *Arthritis Rheum*, 1999, 42: 2319-2324.
- 6 Goethe HS, Steven MM, van der Linden SM, et al. Evaluation of diagnostic criteria for ankylosing spondylitis: a comparison of the Rome, New York and modified New York criteria in patients with a positive clinical history screening test for ankylosing spondylitis. *Br J Rheumatol*, 1985, 24: 242-249.
- 7 Shih HC, Liu SC, Chang CP, et al. Positive association of ankylosing spondylitis with homozygous HLA-B2704, but protection with B2705 in Taiwan Chinese. *Kaohsiung J Med Sci*, 2001, 17: 509-516.
- 8 Duftner C, Goldberger C, Falkenbach A, et al. Prevalence, clinical relevance and characterization of circulating cytotoxic CD4⁺ CD28⁻ T cells in ankylosing spondylitis. *Arthritis Res Ther*, 2003, 5: R292-300.
- 9 Hitchon PW, From AM, Brenton MD, et al. Fractures of the thoracolumbar spine complicating ankylosing spondylitis. *J Neurosurg*, 2002, 97 (2 Suppl): 218-222.
- 10 Chen IH, Chien JT, Yu TC. Transpedicular wedge osteotomy for correction of thoracolumbar kyphosis in ankylosing spondylitis, experience with 78 patients. *Spine*, 2001, 26: E354-360.
- 11 Mehdian SM, Freeman BJ, Licina P. Cervical osteotomy for ankylosing spondylitis: an innovative variation on an existing technique. *Eur Spine J*, 1999, 8: 505-509.
- 12 Yilmaz N, Ozaslan J. Biochemical bone turnover markers in patients with ankylosing spondylitis. *Clin Rheumatol*, 2000, 19: 92-98.
- 13 Sampaio-Barros PD, Costallat LT, Bertolo MB, et al. Methotrexate in the treatment of ankylosing spondylitis. *Scand J Rheumatol*, 2000, 29: 160-162.
- 14 Toussrot E, Ricard-Bhim S, Dumoulin G, et al. Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis. *Rheumatology Oxford*, 1999, 38: 21-27.
- 15 Dos Santos FP, Constantin A, Laroche M, et al. Whole body and regional bone mineral density in ankylosing spondylitis. *J Rheumatol*, 2001, 28: 547-549. (收稿日期: 2003-11-01)

(上接第194页)

减少及骨质疏松发生的因素之一。

参 考 文 献

- 1 杨欣, 郑淑蓉. 选择性雌激素受体调节剂雷洛昔芬的临床研究进展. *中华妇产科杂志*, 2003, 38: 254-256.
- 2 Wang GJ, Moga DB, Richermer WG, et al. Cortisone induced bone changes and its response to lipid clearing agents. *Clin Orthop*, 1978, 130: 81-85.
- 3 Vonder Recke P, Hansoin MA, Haasger C. The association between low bone mass at the menopause and cardiovascular mortality. *Am J Med*, 1999, 106: 273-278.
- 4 Weinstein RS, Nicolas RW, Kirchner JR, et al. Anatomic juxtaposition of apoptotic osteocytes and avascular necrosis in femurs from patients with glucocorticoid excess. *Bone*, 1998, 23: S461.
- 5 朱汉民. 钙与骨质疏松症. *中国骨质疏松杂志*, 2001, 7: 262-266.
- 6 Enlow DH, Conclin JL, Bang Seong. Observation on the occurrence and the distribution of lipids in compact bone. *Clin Orthop*, 1965, 38: 157-169.
- 7 Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. *Clin Orthop*, 2001, 386: 173-178.
- 8 Tomkinson A, Reeve J, Shaw RW, et al. The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone. *J Clin Endocrinol Metab*, 1997, 82: 3128-3135.
- 9 Jones. Alcoholism, hypercortisolemia, fat embolism and osseous avascular necrosis. In: Idiopathic ischemic necrosis of the femoral head in adults. Stuttgart, Germany, Thieme Publ, 1971. 112.
- 10 Daisiro Jr DD, Vogel RL, Jonson TE, et al. High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells. *J Bone Miner Res*, 1998, 13: 96-106.
- 11 Fisher DE. The role of fat embolism in the etiology of corticosteroid-induced avascular necrosis. *Clin Ortho*, 1978, 130: 68-79.
- 12 Ernst M, Heath JK, Rodon GA. Estrogen effects on proliferation messenger ribonucleic acid for collagen and insulin-like growth factor-1, and parathyroid hormone stimulated adenylate cyclase activity in osteoblastic cells from calvariae and long bones. *Endocrinology*, 1989, 125: 825-833. (收稿日期: 2003-11-01)